Dermatologia5 articoli

Impatto 3

Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis.

Pubblicato: 2026-12-01

The Journal of dermatological treatment

MediLens Indicizzato: 2026-05-23

This study evaluated the off-treatment disease control in patients with moderate-to-severe atopic dermatitis (AD) following 12 weeks of abrocitinib 200 mg. In the phase 3 JADE REGIMEN study, patients who achieved significant improvement were randomized to receive either placebo or continued treat...

Leggi su PubMed

Impatto 2

Efficacy and safety of recombinant human epidermal growth factor combined with fractional carbon dioxide laser for facial atrophic acne scars: a systematic review and meta-analysis of randomized trials.

Pubblicato: 2026-05-22

Lasers in medical science

MediLens Indicizzato: 2026-05-23

This systematic review assessed the efficacy and safety of recombinant human epidermal growth factor (rhEGF) combined with fractional CO₂ laser therapy for atrophic acne scars. Twelve randomized controlled trials involving 1,044 patients were analyzed, showing significant reductions in ECCA and V...

Leggi su PubMed

Impatto 2

Research on multi-stage deep learning based intelligent diagnosis of skin diseases and skin medicine diagnosis community construction concept.

Pubblicato: 2026-05-22

Scientific reports

MediLens Indicizzato: 2026-05-23

This study introduces a multi-stage intelligent diagnosis framework utilizing deep learning to enhance dermatological decision-making. The framework employs a LeNet-5 convolutional neural network for initial classification of skin diseases and further assesses disease severity and progression. By...

Leggi su PubMed

Impatto 1

Pregnancy and risk of melanoma: a matched retrospective cohort study.

Pubblicato: 2026-05-22

Melanoma research

MediLens Indicizzato: 2026-05-23

This study investigates the relationship between pregnancy and melanoma risk using a large retrospective cohort. It found no significant increase in the risk of invasive melanoma or melanoma in situ during pregnancy compared to nonpregnant women of reproductive age. The findings suggest that preg...

Leggi su PubMed

Impatto 3

Catestatin peptide impedes melanoma progression and drug resistance by reprogramming oncogenic signaling pathways.

Pubblicato: 2026-05-21

Oncogenesis

MediLens Indicizzato: 2026-05-23

This study investigates catestatin (CST), a peptide derived from Chromogranin A, as a potential therapeutic agent for melanoma. It demonstrates that CST expression decreases with disease progression, suggesting a tumor-suppressive role. Restoration of CST in melanoma cells led to apoptosis and re...

Leggi su PubMed

Tendenze della Ricerca Medica

Dermatologia5 articoli

Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis.

Efficacy and safety of recombinant human epidermal growth factor combined with fractional carbon dioxide laser for facial atrophic acne scars: a systematic review and meta-analysis of randomized trials.

Research on multi-stage deep learning based intelligent diagnosis of skin diseases and skin medicine diagnosis community construction concept.

Pregnancy and risk of melanoma: a matched retrospective cohort study.

Catestatin peptide impedes melanoma progression and drug resistance by reprogramming oncogenic signaling pathways.

Ricevi riassunti giornalieri personalizzati